The University of California, Los Angeles'Jonsson Comprehensive Cancer Center (JCCC) is an NCI designated matrix center conducting a wide range of translational research in the areas of laboratory, clinical and population sciences integrating the activities of 244 members. Based on the JCCC Strategic Plan, the goals of the JCCC are the integration of clinical activities to provide patient-centered care;research infrastructure improvement through technology and shared resources;increased communication within JCCC and to our many audiences;faculty support and development at all levels;and the advancement of emerging areas of research. Over the past funding cycle 70% of patients enrolled in interventional clinical trials participated in investigator-initiated studies. The tota funding base for the JCCC is $163 million with $40 million in NCI funding. Our NCI funding includes subcontracts from other institutions, of which a significant amount is derived from our partnership with California Institute of Technology. In addition, of 3,489 total publications in th reporting period, 35% were published in high-impact journals, 15% were inter-programmatic and 21% were intra-programmatic. Continuing support is requested for the following eight Programs Areas and six Shared Resources. Programs: Cancer and Stem Cell Biology*, Cancer Molecular Imaging, Cancer Nanotechnology*, Gene Regulation, Healthy and At-Risk Populations, Patients and Survivors, Signal Transduction and Therapeutics, Tumor Immunology. (*New Program Area) Shared Resources: Biostatistics, Analytical Support &Evaluation, Genomics, Flow Cytometry, Translational Pathology, Molecular Screening Shared Resource, Small Animal Imaging Shared Resource

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016042-39S2
Application #
8918237
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1996-12-01
Project End
2018-11-30
Budget Start
2014-09-01
Budget End
2014-11-30
Support Year
39
Fiscal Year
2014
Total Cost
$308,000
Indirect Cost
$108,000
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Glenn, Beth A; Hamilton, Ann S; Nonzee, Narissa J et al. (2018) Obesity, physical activity, and dietary behaviors in an ethnically-diverse sample of cancer survivors with early onset disease. J Psychosoc Oncol 36:418-436
Tsai, Wen-Ting K; Wu, Anna M (2018) Aligning physics and physiology: Engineering antibodies for radionuclide delivery. J Labelled Comp Radiopharm 61:693-714
Lisova, Ksenia; Sergeev, Maxim; Evans-Axelsson, Susan et al. (2018) Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors. Nucl Med Biol 61:36-44
Chang, Yu-Ling; Rossetti, Maura; Vlamakis, Hera et al. (2018) A screen of Crohn's disease-associated microbial metabolites identifies ascorbate as a novel metabolic inhibitor of activated human T cells. Mucosal Immunol :
Jia, Qingmei; Bowen, Richard; Dillon, Barbara Jane et al. (2018) Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia. Sci Rep 8:7009
Kiertscher, Sylvia M; Gangalum, Pallavi R; Ibrahim, Grace et al. (2018) A Prospective Study of Humoral and Cellular Immune Responses to Hepatitis B Vaccination in Habitual Marijuana Smokers. J Neuroimmune Pharmacol 13:219-229
Van, Christina; Condro, Michael C; Lov, Kenny et al. (2018) PACAP/PAC1 Regulation of Inflammation via Catecholaminergic Neurons in a Model of Multiple Sclerosis. J Mol Neurosci :
Leoh, Lai Sum; Kim, Yoon Kyung; Candelaria, Pierre V et al. (2018) Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma. J Immunol 200:3485-3494
Hicks, Michael R; Hiserodt, Julia; Paras, Katrina et al. (2018) ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs. Nat Cell Biol 20:46-57
Tsang, Eric J; Wu, Benjamin; Zuk, Patricia (2018) MAPK signaling has stage-dependent osteogenic effects on human adipose-derived stem cells in vitro. Connect Tissue Res 59:129-146

Showing the most recent 10 out of 767 publications